Wandercraft, a leader in self-balancing robotic mobility systems, today announced that it has secured $75 million funding and financing as part of its Series D round, with significant contributions from Renault Group, PSIM fund, managed on behalf of the French State by Bpifrance as part of the France 2030 plan, Teampact Ventures and Quadrant Management. Other participants in the Series D round include LBO France, Mutuelles Impact – Managed by XAnge, Cemag Invest, Martagon Capital, and AG2R LA MONDIALE.
Renault Group partnership: The news comes off the back of Wandercraft’s announcement with Renault Group, in which the car manufacturer now has a minority stake ownership and a strategic partnership with Wandercraft. And the partnership brings Renault Group’s industrial expertise to scale up production of Wandercraft’s exoskeletons and industrial robots, laying the groundwork for cost-efficient scaling of Eve and the broader Calvin humanoid family. Renault Group is also Wandercraft’s first commercial partner and customer of Calvin-40, named for its development time of just 40 days.
Calvin-40: Calvin-40 is an industrial-grade robot intended for physically demanding tasks and the first humanoid robot developed by a European company. Calvin-40’s rapid development was made possible by utilizing Wandercraft’s rapid development process and an existing, leading-edge robotics platform integrated with NVIDIA Isaac technologies, including the NVIDIA Isaac GR00T N1 foundation model and the NVIDIA Jetson edge AI platform.
How the funding will be used: This funding round coincides with a period of rapid growth, increased global visibility, and product innovation in clinical, consumer, and industrial robotics. And the new funding will help propel Wandercraft into its next phase of growth: bringing Eve, the world’s first self-balancing personal exoskeleton, to market as early as 2026; expanding clinical adoption of its flagship rehabilitation system, Atalante X; and developing and deploying Calvin-40, its humanoid robot.
The funding will be used to accelerate the commercial deployment of Eve and the industrial development and rollout of Calvin-40 and the broader Calvin humanoid family.
KEY QUOTES:
“The momentum we’ve achieved over the past few years is extraordinary. We’ve expanded globally, launched pivotal clinical trials, readied the commercialization of Eve, our personal exoskeleton, and entered a landmark partnership with Renault Group. This funding allows us to continue our mission of transforming how people live, move, and work across rehabilitation, home environments, and soon on factory floors.”
Matthieu Masselin, CEO and Co-founder of Wandercraft
“We are delighted to renew our support for Wandercraft, which has been supported by the State with Bpifrance since 2017. This Series D alongside Renault Group will enable the company to accelerate the industrial deployment of its unique robotics technology and make the Eve exoskeleton accessible to as many people as possible. Access to health and mobility for all is indeed a strategic focus supported by the French State through the France 2030 plan.”
Paul-François Fournier, Executive Director of Bpifrance Innovation
